Genetically Engineered T Cells targeting NY-ESO-1/LAGE-1a
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Genetically Engineered T Cells targeting NY-ESO-1/LAGE-1a, covering 2026-04-17 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors [Phase 2]